Stock Alert: Applied DNA Sciences Stock Surges 94% In Premarket

Shares of Applied DNA Sciences Inc. (APDN) are soaring over 94% in pre-market today, after the company and Takis Biotech announced the production of neutralizing antibodies against SARS-CoV-2 after DNA vaccination in animals.

Applied DNA Sciences and Takis announced that the first injections of the DNA vaccine candidates against the Spike protein (product of the S gene) of the SARS-CoV-2 virus, cause of the COVID-19 disease, have produced neutralizing antibodies in test animals.

These initial results were obtained using plasmids to baseline results; Applied DNA's linear DNA dose-response trials begin this week.

The Joint Development Agreement between Takis and Applied DNA Sciences calls for the manufacture of the DNA vaccine candidates for both preclinical and human trials via Applied DNA's proprietary and patented LinearDNA PCR (Polymerase Chain Reaction) platform.

APDN has been trading in the range of $2.52 - $33.60 for the past one year, and closed Friday's trade at $6.63, up 44 cents or 7.11%. The stock is currently trading at $12.87, up $6.24 or 94.12% in the pre-market trading session.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Follow RTT